N-methyl-4-(6-oxo-1-(2-(3-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)quinolin-6-yl)ethyl)-1,6-dihydropyridazin-3-yl)-2-(trifluoromethyl)benzamide

ID: ALA5177753

Chembl Id: CHEMBL5177753

PubChem CID: 168273686

Max Phase: Preclinical

Molecular Formula: C32H30F3N7O2

Molecular Weight: 601.63

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1ccc(-c2ccc(=O)n(CCc3ccc4ncc(-c5cnn(C6CCNCC6)c5)cc4c3)n2)cc1C(F)(F)F

Standard InChI:  InChI=1S/C32H30F3N7O2/c1-36-31(44)26-4-3-21(16-27(26)32(33,34)35)29-6-7-30(43)41(40-29)13-10-20-2-5-28-22(14-20)15-23(17-38-28)24-18-39-42(19-24)25-8-11-37-12-9-25/h2-7,14-19,25,37H,8-13H2,1H3,(H,36,44)

Standard InChI Key:  PGYVYYYFZQHUPY-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5177753

    ---

Associated Targets(Human)

MET Tclin Hepatocyte growth factor receptor (10718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hs746T (53 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 601.63Molecular Weight (Monoisotopic): 601.2413AlogP: 4.87#Rotatable Bonds: 7
Polar Surface Area: 106.73Molecular Species: BASEHBA: 8HBD: 2
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.76CX Basic pKa: 10.12CX LogP: 3.43CX LogD: 0.82
Aromatic Rings: 5Heavy Atoms: 44QED Weighted: 0.28Np Likeness Score: -1.42

References

1. Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W, Zhou Y, Tu Z, Chen Y, Zhang Z, Lu X..  (2022)  Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.,  65  (22.0): [PMID:36355693] [10.1021/acs.jmedchem.2c00981]

Source